Psychiatric and Behavioural Side Effects Associated With Perampanel in Patients With Temporal Lobe Epilepsy. A Real-World Experience

被引:8
|
作者
Mammi, Anna [1 ,2 ]
Ferlazzo, Edoardo [1 ,2 ]
Gasparini, Sara [1 ,2 ]
Bova, Valentina [2 ]
Neri, Sabrina [1 ,2 ]
Labate, Angelo [3 ]
Mastroianni, Giovanni [1 ,2 ]
Bianco, Concetta Lo [1 ,2 ]
Cianci, Vittoria [2 ]
Aguglia, Umberto [1 ,2 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy
[2] Great Metropolitan Hosp BMM, Reg Epilepsy Ctr, Reggio Di Calabria, Italy
[3] Univ Messina, Dept BIOMORF, Neurol Unit, Messina, Italy
来源
FRONTIERS IN NEUROLOGY | 2022年 / 13卷
关键词
adverse effects; focal epilepsy; psychosis; irritability; anti-seizure medications; AMPA-RECEPTOR ANTAGONIST; RANDOMIZED PHASE-III; ADJUNCTIVE PERAMPANEL; ANTIEPILEPTIC DRUGS; ILAE COMMISSION; THERAPY; CLASSIFICATION; ADULTS;
D O I
10.3389/fneur.2022.839985
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychiatric and behavioural side effects are common, undesirable effects associated with antiseizure medication use. Temporal lobe epilepsy is the most common focal epilepsy in adults and it is frequently associated with drug resistance. Patients with intractable epilepsy are more likely to have psychiatric and behavioural side effects when taking antiseizure medications and seem to be at higher risk for psychiatric comorbidities. Perampanel is a novel anti-seizure medication approved for focal and generalised epilepsies as add-on therapy. This is a 12-week short-term observational prospective study on people with focal epilepsy consecutively recruited from an Italian tertiary epilepsy centre, aimed to compare incidence and severity of psychiatric and behavioural side effects associated with perampanel use in patients with temporal lobe epilepsy as compared to other focal epilepsies. All patients received add-on perampanel according to indication and clinical judgement. Incidence and severity of psychiatric and behavioural side effects were rated by Neuropsychiatric Inventory Questionnaire. All patients enrolled answered the questionnaire before starting perampanel and after 12 weeks of treatment. We found no significant difference in terms of incidence and severity of psychiatric and behavioural side effects associated with perampanel in patients with temporal lobe epilepsy as compared to other focal epilepsies. In line with the literature, the most common adverse effects were "irritability" for both groups and "aggression" for patients with other focal epilepsies.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Perampanel monotherapy in epilepsy patients with focal and generalised seizures: real-world experience
    Alsaadi, Taoufik
    Toledo Agrany, Manuel
    Ayuga Loro, Fernando
    Trinka, Eugen
    Wu, Tony
    Malhotra, Manoj
    Ngo, Leock Y.
    Villanueva, Vicente
    EPILEPSIA, 2021, 62 : 152 - 153
  • [2] Perampanel Monotherapy in Epilepsy Patients with Focal and Generalized Seizures: Real-World Experience
    Alsaadi, Taoufik
    Toledo, Manuel
    Loro, Fernando Ayuga
    Trinka, Eugen
    Wu, Tony
    Malhotra, Manoj
    Ngo, Leock Y.
    Villanueva, Vicente
    NEUROLOGY, 2021, 96 (15)
  • [3] Real-world analysis of hospitalizations in patients with epilepsy and treated with perampanel
    Faught, Edward
    Li, Xuan
    Choi, Jiyoon
    Malhotra, Manoj
    Knoth, Russell L.
    EPILEPSIA OPEN, 2021, 6 (04) : 645 - 652
  • [4] Real-world hospitalization risk in patients with epilepsy treated with perampanel
    Li, Xuan
    Frech, Feride
    Plauschinat, Craig A.
    Gore, Mugdha
    EPILEPSY & BEHAVIOR, 2021, 114
  • [5] Two-year real-world experience of perampanel in elderly patients with refractory focal epilepsy
    Rohracher, A.
    Deak, I.
    Dobesberger, J.
    Hoefler, J.
    Kalss, G.
    Kuchukhidze, G.
    Leitinger, M.
    Trinka, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 388 - 388
  • [6] Plasma Concentration, Efficacy, and Tolerability of Perampanel in Chinese Pediatric Patients with Epilepsy: Real-World Clinical Experience
    Zhao, Ting
    Li, Hong-Jian
    Zhang, Hui-lan
    Feng, Ji-Rong
    Yu, Jing
    Feng, Jie
    Wang, Ting-ting
    Sun, Yan
    Yu, Lu-Hai
    THERAPEUTIC DRUG MONITORING, 2024, 46 (01) : 111 - 117
  • [7] Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data
    Rohracher, Alexandra
    Kalss, Gudrun
    Leitinger, Markus
    Granbichler, Claudia
    Deak, Ildiko
    Dobesberger, Judith
    Kuchukhidze, Giorgi
    Thomschewski, Aljoscha
    Hoefler, Julia
    Trinka, Eugen
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (06) : 445 - 453
  • [8] Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience
    Chang, Richard Shek-Kwan
    Lui, Hoi Ki Kate
    Leung, Yu Hin Ian
    Leung, William C. Y.
    Yam, Ka Keung
    Wang, Yujie
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [9] Real-world experience of treating patients aged <12 years with perampanel
    Auvin, Stephane
    Garcia-Ron, Adrian
    Zimmermann, Georg
    Wu, Tony
    D'Souza, Wendyl
    Ngo, Leock Y.
    Villanueva, Vicente
    EPILEPSIA, 2021, 62 : 151 - 151
  • [10] Treatment of adult epilepsy patients with Perampanel: evidence from real-world studies
    Strzelczyk, A.
    Segal, E.
    Wehner, T.
    Ngo, L. Y.
    Fuertes, R. Sainz
    Carreno, M.
    Wu, T.
    Steinhoff, B. J.
    Villanueva, V.
    EPILEPSIA, 2023, 64 : 288 - 288